Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.42 |
| ▸ | BPTF | Q12830 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 6/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 4/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30066438 | 0.80 | PDE10A (0.43) | JAK2JAK1TYK2JAK3PTGER4 | |
| SCHEMBL24669937 | 0.80 | PDE10A (0.43) | JAK2JAK1TYK2JAK3PTGER4 | |
| SCHEMBL18940311 | 0.80 | PTGER4 (0.43) | JAK2JAK1TYK2JAK3PTGER4 | |
| SCHEMBL18940291 | 0.79 | SMO (0.42) | JAK2JAK1TYK2JAK3PTGER4 | |
| SCHEMBL15509072 | 0.78 | METAP2 (0.46) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL15509173 | 0.78 | METAP2 (0.46) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL15515890 | 0.78 | METAP2 (0.46) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL15616205 | 0.78 | GRIN1 (0.38) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL23603068 | 0.77 | JAK2 (0.37) | JAK2JAK1TYK2JAK3MAP4K4 | |
| SCHEMBL10324203 | 0.76 | HSD11B1 (0.46) | JAK2JAK1TYK2JAK3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3974413-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3082786-B1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME (US) | 2021-10-27 | — | — | EP | disclosed |
| US-9834563-B2 | Antidiabetic substituted heteroaryl compounds | MERCK SHARP & DOHME CORP. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170166578-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-06-15 | — | — | US | disclosed |
| EP-3082786-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015089809-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095256-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166578-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | GPR119, GPR65, GPR55 | JAK2 1771/4885JAK1 3516/4885TYK2 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.